On the Decline

The Wall Street Journal's Health Blog has put together a chart of R&D spending by US drug companies — a related article in the paper said that R&D fell in 2009 by 3.8 percent to $382.6 billion. Pfizer and Johnson and Johnson's spending dropped by 10.8 and 12.7 percent, respectively while the other companies showed gains in spending.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York Times and ProPublica say that many physicians fail to disclose their financial ties when publishing in medical journals.

The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.

Science reports that the US National Cancer Institute is cutting its operating budget by 5 percent.

In PLOS this week: similar variants seen in bullbogs, people with Robinow syndrome; ApoE genotypes in African-American, Puerto Rican populations; and more.